Keynote Session: CAR T-cell Therapy - Focus on Lymphomas

Chimeric antigen receptor (CAR) T-cell therapy is a new and rapidly evolving immunotherapy emerging as a novel treatment option for relapsed or refractory lymphomas. Axicabtagene ciloleucel and tisagenlecleucel are the two FDA approved anti-CD19 CAR T-cell therapies for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after ≥2 prior systemic therapy regimens.  CAR T-cell therapy represents a major paradigm shift from the conventional management strategies for relapsed or refractory lymphomas.  Multidisciplinary approach is required for the monitoring and management of acute toxicities to prevent fatal outcomes in patients treated with CAR-T-cell therapy.  There is a clear need to educate clinicians regarding the special considerations for the administration of CAR T-cell therapy in appropriately selected patients, the unique spectrum of treatment-related adverse events, and the effective management strategies.  Continuing education and practical advice from experts in CAR T-cell therapy should enable clinicians to incorporate these potentially curative treatment options and strategies for the management of unique toxicities into their clinical practice in appropriately selected patients with relapsed or refractory DLBCL and other subtypes of lymphomas.

This information was originally presented at the NCCN 13th Annual Congress: Hematologic Malignancies™ held in New York, New York, from September 21-22, 2018.

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Review the evidence from key clinical studies that have evaluated CAR T-cell therapy for relapsed/refractory DLBCL and other subtypes of lymphomas. 
  • Describe the strategies for the management of unique toxicities associated with CAR T-cell therapies.
  • Integrate CAR T-cell therapy into the overall treatment plan in appropriate patients with relapsed/refractory DLBCL.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas
  • AstraZeneca
  • Celgene Corporation
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • MEI Pharma
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer
  • Sanofi Genzyme
  • Takeda Oncology

This activity is supported by independent educational grants from AbbVie and Incyte.

This activity is supported by educational funding provided by Amgen.

This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Course opens: 
11/01/2018
Course expires: 
11/01/2019
Cost:
$0.00

Reem Karmali, MD, MS
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s, and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Definitions

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses the following relevant financial relationships:

Reem Karmali, MD, MS
AstraZeneca Pharmaceuticals LP: Product/Speakers Bureau
Gilead Sciences, Inc.: Product/Speakers Bureau

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (employed by NCCN until 8/10/2018); Joan S. McClure, MS (employed by NCCN until 8/1/2018); Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Gary J. Weyhmuller, MBA, SPHR

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:

Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options

Katherine Pierce
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Hema Sundar, PhD

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.50 hour of Category 1 credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 0.50 contact hour.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 0.50 contact hour (0.05 CEUs) of continuing education credit. UAN: 0836-0000-18-136-H01-P

Available Credit

  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation

Accreditation Period

Course opens: 
11/01/2018
Course expires: 
11/01/2019

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: